Skip to main content
Lytix Biopharma AS logo

Lytix Biopharma AS — Investor Relations & Filings

Ticker · LYTIX ISIN · NO0010405780 LEI · 549300NXMIMRSBCDZO71 OL Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2024-04-26 Capital/Financing Update
Country NO Norway
Listing OL LYTIX

About Lytix Biopharma AS

https://www.lytixbiopharma.com/

Lytix Biopharma AS is a clinical-stage immuno-oncology company that develops a proprietary platform of oncolytic molecules for cancer treatment. The company's technology is based on molecules designed to selectively target and lyse cancer cell membranes. This process releases a broad spectrum of tumor antigens, which in turn stimulates a patient's immune system to recognize and attack the cancer, effectively turning immunologically "cold" tumors "hot". Its lead drug candidate, ruxotemitide, is being evaluated in clinical trials as a neoadjuvant treatment for various solid tumors, including melanoma and basal cell carcinoma.

Recent filings

Filing Released Lang Actions
LYTIX BIOPHARMA AS – SHARE ISSUE PURSUANT TO BOARD AUTHORIZATION
Capital/Financing Update Classification · 98% confidence The document explicitly announces a 'SHARE ISSUE PURSUANT TO BOARD AUTHORIZATION' and details the issuance of new shares (486,377 Offer Shares) to settle pre-commitment and guarantee fees related to a prior share offering. This action directly concerns the company's capital structure and the issuance of new equity. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP), which covers fundraising, financing activities, or capital structure changes. While it involves shares, it is a specific financing event rather than a general share repurchase (POS) or a general announcement of a capital change (SHA), although SHA is a close secondary possibility. Given the context of settling fees via a share issue following a general meeting resolution, CAP is the most precise fit.
2024-04-26 English
Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates
Director's Dealing Classification · 100% confidence The document text consists of structured tables detailing transactions involving shares of Lytix Biopharma AS by individuals identified as having managerial responsibilities (Chief Scientific Officer, Chief Financial Officer) and closely associated persons. The nature of the transaction is 'Subscription and allocation of shares'. This format and content strongly indicate a mandatory disclosure of insider trading or transactions by persons discharging managerial responsibilities (PDMRs) and their closely associated persons. In the provided definitions, 'Director's Dealing' (DIRS) is the most appropriate category for reporting personal share transactions by directors and executives (insider trades).
2024-04-25 English
Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates
Share Issue/Capital Change Classification · 99% confidence The document is titled "Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates" and details the allocation of new shares in a share offering to primary insiders and their close associates. This directly concerns personal share transactions by company directors and executives (insider trades), which aligns perfectly with the definition of Director's Dealing (DIRS). Although it mentions a share offering (CAP), the core purpose and regulatory context (Article 19 MAR) are focused on reporting the resulting insider transactions, making DIRS the most specific classification. The document length is short, but it is a direct notification, not an announcement of a separate report.
2024-04-25 English
LYTIX BIOPHARMA AS – MINUTES OF EXTRAORDINARY GENERAL MEETING AND FINAL RESULTS OF SHARE OFFERING
AGM Information Classification · 99% confidence The document is explicitly titled 'MINUTES FROM EXTRAORDINARY GENERAL MEETING' ('PROTOKOLL FRA EKSTRAORDINÆR GENERALFORSAMLING'). It details the proceedings, resolutions passed (including a share capital increase and board authorization), and the attendance record of a specific meeting held on April 25, 2024. This content perfectly matches the definition of materials shared during a General Meeting. The closest specific code is AGM-R (AGM Information), as an Extraordinary General Meeting (EGM) falls under the general category of shareholder meetings, distinct from standard regulatory reports (10-K, IR) or simple announcements (RPA, RNS).
2024-04-25 Norwegian
LYTIX BIOPHARMA AS – MINUTES OF EXTRAORDINARY GENERAL MEETING AND FINAL RESULTS OF SHARE OFFERING
AGM Information Classification · 95% confidence The document explicitly mentions 'MINUTES OF EXTRAORDINARY GENERAL MEETING' and details resolutions passed by the 'extraordinary general meeting (the "EGM")' regarding the approval of a share offering and the issuance of shares. This content directly relates to the formal outcomes and records of a shareholder meeting, which aligns best with the 'AGM Information' category, even though it is an EGM rather than an AGM, as AGM-R is the closest fit for general meeting records/results among the provided codes. It also details the final results of a share offering, which involves capital structure changes, but the primary context is the formal meeting minutes and resolutions. Comparing with definitions: - AGM-R (AGM Information): Closest fit for EGM minutes and resolutions. - CAP (Capital/Financing Update): Relevant due to the share offering, but the document is framed as the official minutes/results of the meeting that approved it. - DVA (Declaration of Voting Results & Voting Rights Announcements): This document contains the resolution (the result of the vote), making AGM-R or DVA plausible. However, 'Minutes' suggests a broader record than just the vote tally, leaning towards AGM-R as the record of the meeting. Given the title 'MINUTES OF EXTRAORDINARY GENERAL MEETING', AGM-R is the most appropriate classification for the formal record of the meeting's decisions.
2024-04-25 English
Lytix Biopharma annonserer godkjennelse av fase II-studie i pasienter med tidligfase føflekkreft (melanom) - en betydelig kommersiell mulighet
Regulatory Filings Classification · 95% confidence The document is a press release from Lytix Biopharma announcing the approval of a Phase II clinical trial (NeoLIPA) for their drug candidate LTX-315 in early-stage melanoma patients. It details the study design, the medical rationale, the principal investigator, and the expected commercial opportunity. This type of announcement, focusing on clinical trial progress, regulatory milestones (approval by the Directorate of Medical Products), and future pipeline expectations, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a detailed announcement about clinical development and strategy rather than a formal financial report (10-K, IR, ER) or a simple notice of a report being published (RPA), Investor Presentation (IP) is the most fitting category, as these releases often serve as the primary communication tool for investors regarding operational milestones.
2024-04-25 Norwegian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.